Trials / Active Not Recruiting
Active Not RecruitingNCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
Detailed description
Primary Objectives: \- To assess the complete remission (CR) rate of magrolimab in combination with pembrolizumab in adult subjects with relapsed or refractory cHL Secondary Objectives: * To assess the safety and tolerability of magrolimab in combination with pembrolizumab in adult subjects with relapsed or refractory cHL * To assess the overall response rate (ORR)
Conditions
- Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Relapsed Classical Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magrolimab | 45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion |
| DRUG | Pembrolizumab | 200 mg IV infusion |
| PROCEDURE | PET/CT | Scan |
Timeline
- Start date
- 2022-06-21
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
- First posted
- 2021-03-09
- Last updated
- 2025-04-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04788043. Inclusion in this directory is not an endorsement.